{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:22:57Z","timestamp":1786123377980,"version":"build-2736575974"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND:<\/jats:title>\n                    <jats:p>Remimazolam, a novel short-acting benzodiazepine, is associated with more stable intraoperative hemodynamics than propofol. Older adults undergoing hip fracture surgery represent a vulnerable population at elevated risk for perioperative cardiovascular complications. However, whether remimazolam\u2019s hemodynamic advantages translate into reduced major adverse cardiovascular events (MACE) in this population remains uncertain, particularly given recent randomized trials questioning the relationship between intraoperative blood pressure management and postoperative outcomes. We aimed to compare 30-day in-hospital MACE and all-cause in-hospital mortality after general anesthesia with remimazolam versus propofol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study using a target trial emulation framework with data from a multicenter Japanese hospital administrative database (September 1, 2020, to September 30, 2024). Eligible participants were adults aged 65 to 99 years undergoing hip fracture surgery who received total intravenous anesthesia with remimazolam or propofol on the day of surgery. The primary outcome was 30-day in-hospital MACE, and the secondary outcome was 30-day all-cause in-hospital mortality. We estimated the average treatment effect among patients who received remimazolam compared with propofol using propensity score weighting. Risks and 95% confidence intervals (CIs) were obtained from weighted cumulative incidence functions with bootstrap resampling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      Of 132,422 patients identified, 14,027 were included in the analysis. The primary outcome occurred in 2.86% of the remimazolam group and 2.74% of the propofol group, with no meaningful difference between groups (risk ratio, 1.04 [95% CI, 0.80\u20131.38];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.76; risk difference, 0.12% [95% CI, \u22120.64% to 0.90%]). Thirty-day all-cause in-hospital mortality also did not differ materially between groups (risk ratio, 1.03 [95% CI, 0.61\u20131.80];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.91). These findings remained consistent across sensitivity analyses and in subgroup analyses stratified by baseline cardiovascular risk.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Among older adults undergoing hip fracture surgery, 30-day in-hospital MACE and mortality did not differ substantially between remimazolam and propofol, suggesting that anesthetic selection between these agents may not substantially affect short-term cardiovascular outcomes in this high-risk population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1213\/ane.0000000000008161","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T15:01:49Z","timestamp":1781535709000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Major Adverse Cardiovascular Events After Hip Fracture Surgery with Remimazolam or Propofol Total Intravenous Anesthesia: A Retrospective Cohort Study Emulating a Target Trial"],"prefix":"10.1213","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8471-3539","authenticated-orcid":false,"given":"Yuki","family":"Okazawa","sequence":"first","affiliation":[{"name":"Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan"},{"name":"Department of Anesthesiology and Critical Care, Kobe City Medical Center General Hospital, Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7147-0737","authenticated-orcid":false,"given":"Toshiki","family":"Fukasawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaki","family":"Yoshiyama","sequence":"additional","affiliation":[{"name":"Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan"},{"name":"Department of Orthopedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Anno","sequence":"additional","affiliation":[{"name":"Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7477-4071","authenticated-orcid":false,"given":"Koji","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"R1-20260615","doi-asserted-by":"crossref","first-page":"1","DOI":"10.17085\/apm.21115","article-title":"Remimazolam: pharmacological characteristics and clinical applications in anesthesiology.","volume":"17","author":"Kim","year":"2022","journal-title":"Anesth Pain Med"},{"key":"R2-20260615","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s13318-025-00963-2","article-title":"Clinical pharmacokinetics, pharmacodynamics, and drug interactions of remimazolam.","volume":"50","author":"Murrell","year":"2025","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"R3-20260615","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bja.2021.03.028","article-title":"Current status of perioperative hypnotics, role of benzodiazepines, and the case for remimazolam: a narrative review.","volume":"127","author":"Sneyd","year":"2021","journal-title":"Br J Anaesth"},{"key":"R4-20260615","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1097\/EJA.0000000000002042","article-title":"Remimazolam vs. propofol for general anaesthesia in elderly patients: a meta-analysis with trial sequential analysis.","volume":"41","author":"Pereira","year":"2024","journal-title":"Eur J Anaesthesiol"},{"key":"R5-20260615","doi-asserted-by":"crossref","first-page":"e580","DOI":"10.1016\/S2666-7568(21)00172-0","article-title":"Global, regional, and national burden of bone fractures in 204 countries and territories, 1990-2019: a systematic analysis from the global burden of disease study 2019.","volume":"2","year":"2021","journal-title":"Lancet Healthy Longev"},{"key":"R6-20260615","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.bja.2024.07.022","article-title":"Trends in hip fracture surgery in the United States from 2016 to 2021: patient characteristics, clinical management, and outcomes.","volume":"133","author":"Hong","year":"2024","journal-title":"Br J Anaesth"},{"key":"R7-20260615","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1136\/bmj.38643.663843.55","article-title":"Effect of comorbidities and postoperative complications on mortality after hip fracture in elderly people: prospective observational cohort study.","volume":"331","author":"Roche","year":"2005","journal-title":"BMJ"},{"key":"R8-20260615","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1001\/jama.2025.17235","article-title":"Individualized perioperative blood pressure management in patients undergoing major abdominal surgery: the IMPROVE-multi randomized clinical trial.","volume":"334","author":"Saugel","year":"2025","journal-title":"JAMA"},{"key":"R9-20260615","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1001\/jama.2025.18007","article-title":"Proactive vs reactive treatment of hypotension during surgery: the PRETREAT randomized clinical trial.","volume":"334","author":"Kant","year":"2025","journal-title":"JAMA"},{"key":"R10-20260615","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.bja.2023.08.026","article-title":"Intraoperative hypotension and postoperative outcomes: a meta-analysis of randomised trials.","volume":"131","author":"D\u2019Amico","year":"2023","journal-title":"Br J Anaesth"},{"key":"R11-20260615","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12871-025-02976-5","article-title":"Intraoperative hypotension and postoperative risks in non-cardiac surgery: a meta-analysis.","volume":"25","author":"Qin","year":"2025","journal-title":"BMC Anesthesiol"},{"key":"R12-20260615","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/jama.2025.13350","article-title":"Transparent reporting of observational studies emulating a target trial-the TARGET statement.","volume":"334","author":"Cashin","year":"2025","journal-title":"JAMA"},{"key":"R13-20260615","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/jgf2.367","article-title":"Data resource profile: JMDC claims databases sourced from Medical Institutions.","volume":"21","author":"Nagai","year":"2020","journal-title":"J Gen Fam Med"},{"key":"R14-20260615","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2188\/jea.JE20200288","article-title":"History and profile of diagnosis procedure combination (DPC): development of a real data collection system for acute inpatient care in Japan.","volume":"31","author":"Hayashida","year":"2021","journal-title":"J Epidemiol"},{"key":"R15-20260615","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/pds.5636","article-title":"Validation studies of Japanese administrative health care data: a scoping review.","volume":"32","author":"Yamana","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R16-20260615","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2188\/jea.JE20210024","article-title":"Validation study of diabetes definitions using japanese diagnosis procedure combination data among hospitalized patients.","volume":"33","author":"Kanehara","year":"2023","journal-title":"J Epidemiol"},{"key":"R17-20260615","doi-asserted-by":"crossref","first-page":"e70063","DOI":"10.1002\/pds.70063","article-title":"Impact of early resumption of oral anticoagulation on recurrence after surgery for chronic subdural hematoma in patients with atrial fibrillation: a target trial emulation.","volume":"33","author":"Anno","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R18-20260615","doi-asserted-by":"crossref","first-page":"112215","DOI":"10.1016\/j.injury.2025.112215","article-title":"Cefazolin vs. alternative beta-lactams for prophylaxis in lower extremity fracture surgery: a target trial emulation.","volume":"56","author":"Yoshiyama","year":"2025","journal-title":"Injury"},{"key":"R19-20260615","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available.","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"key":"R20-20260615","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/0270-0255(86)90088-6","article-title":"A new approach to causal inference in mortality studies with a sustained exposure period\u2014application to control of the healthy worker survivor effect.","volume":"7","author":"Robins","year":"1986","journal-title":"Math Model"},{"key":"R21-20260615","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/pds.5213","article-title":"Accuracy of Japanese claims data in identifying diabetes-related complications.","volume":"30","author":"Fujihara","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R22-20260615","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1002\/sim.8471","article-title":"A causal framework for classical statistical estimands in failure-time settings with competing events.","volume":"39","author":"Young","year":"2020","journal-title":"Stat Med"},{"key":"R23-20260615","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","article-title":"Marginal structural models and causal inference in epidemiology.","volume":"11","author":"Robins","year":"2000","journal-title":"Epidemiology"},{"key":"R24-20260615","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/01.EDE.0000081989.82616.7d","article-title":"Marginal structural models as a tool for standardization.","volume":"14","author":"Sato","year":"2003","journal-title":"Epidemiology"},{"key":"R25-20260615","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.je.2016.09.009","article-title":"Validity of diagnoses, procedures, and laboratory data in Japanese administrative data.","volume":"27","author":"Yamana","year":"2017","journal-title":"J Epidemiol"},{"key":"R26-20260615","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"key":"R27-20260615","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0140-6736(20)30058-1","article-title":"Accelerated surgery versus standard care in hip fracture (HIP ATTACK): an international, randomised, controlled trial.","volume":"395","year":"2020","journal-title":"Lancet"},{"key":"R28-20260615","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies.","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"R29-20260615","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jclinepi.2021.01.008","article-title":"Framework for the treatment and reporting of missing data in observational studies: the treatment and reporting of missing data in observational studies framework.","volume":"134","author":"Lee","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"R30-20260615","doi-asserted-by":"crossref","first-page":"e076460","DOI":"10.1136\/bmj-2023-076460","article-title":"Process guide for inferential studies using healthcare data from routine clinical practice to evaluate causal effects of drugs (PRINCIPLED): considerations from the FDA sentinel innovation center.","volume":"384","author":"Desai","year":"2024","journal-title":"BMJ"},{"key":"R31-20260615","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1161\/01.CIR.100.10.1043","article-title":"Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery.","volume":"100","author":"Lee","year":"1999","journal-title":"Circulation"},{"key":"R32-20260615","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jclinepi.2021.08.028","article-title":"Causal analyses of existing databases: no power calculations required.","volume":"144","author":"Hern\u00e1n","year":"2022","journal-title":"J Clin Epidemiol"},{"key":"R33-20260615","author":"Gerds","year":"2025","journal-title":"Prodlim: Product-Limit Estimation For Censored Event History Analysis. R Package Version 2025.04.28"},{"key":"R34-20260615","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/bja\/aew126","article-title":"The effect of propofol on haemodynamics: cardiac output, venous return, mean systemic filling pressure, and vascular resistances.","volume":"116","author":"de Wit","year":"2016","journal-title":"Br J Anaesth"},{"key":"R35-20260615","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1097\/00000542-199812000-00028","article-title":"Propofol-induced increase in vascular capacitance is due to inhibition of sympathetic vasoconstrictive activity.","volume":"89","author":"Hoka","year":"1998","journal-title":"Anesthesiology"},{"key":"R36-20260615","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.bja.2018.04.036","article-title":"Intraoperative hypotension and the risk of postoperative adverse outcomes: a systematic review.","volume":"121","author":"Wesselink","year":"2018","journal-title":"Br J Anaesth"},{"key":"R37-20260615","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.bja.2023.09.005","article-title":"Intraoperative blood pressure: could less be more?","volume":"131","author":"Michard","year":"2023","journal-title":"Br J Anaesth"},{"key":"R38-20260615","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.bja.2022.01.012","article-title":"Hypotension as a marker or mediator of perioperative organ injury: a narrative review.","volume":"128","author":"Ackland","year":"2022","journal-title":"Br J Anaesth"},{"key":"R39-20260615","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1056\/NEJMra1502824","article-title":"Cardiac complications in patients undergoing major Noncardiac surgery.","volume":"373","author":"Devereaux","year":"2015","journal-title":"N Engl J Med"},{"key":"R40-20260615","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.bja.2024.04.046","article-title":"PeriOperative quality initiative (POQI) international consensus statement on perioperative arterial pressure management.","volume":"133","author":"Saugel","year":"2024","journal-title":"Br J Anaesth"},{"key":"R41-20260615","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","article-title":"External validity of randomised controlled trials: \u201cto whom do the results of this trial apply?\u201d.","volume":"365","author":"Rothwell","year":"2005","journal-title":"Lancet"},{"key":"R42-20260615","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJM200006223422507","article-title":"Randomized, controlled trials, observational studies, and the hierarchy of research designs.","volume":"342","author":"Concato","year":"2000","journal-title":"N Engl J Med"},{"key":"R43-20260615","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1213\/ANE.0000000000007833","article-title":"Reconciling observational signals with trial data in anesthetic choice for hip fracture surgery.","volume":"142","author":"Fettiplace","year":"2026","journal-title":"Anesth Analg"}],"container-title":["Anesthesia &amp; Analgesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1213\/ANE.0000000000008161","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:33:51Z","timestamp":1786113231000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1213\/ANE.0000000000008161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":43,"URL":"https:\/\/doi.org\/10.1213\/ane.0000000000008161","relation":{},"ISSN":["0003-2999","1526-7598"],"issn-type":[{"value":"0003-2999","type":"print"},{"value":"1526-7598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]}}}